The ASCO 2024 conference is set to showcase groundbreaking advancements in the field of genitourinary cancers, with a focus on prostate cancer, bladder/urothelial cancer, and renal cell carcinoma. Major pharmaceutical companies such as Novartis, Pfizer, Merck, Arvinas, Astellas Pharma, Janssen, Orion Pharma, and others are gearing up to present their latest research and developments, which are expected to generate significant interest and discussion throughout the event.

Prostate cancer remains the most prevalent cancer among males in the United States, with approximately 3,803,500 prevalent cases in 2023. This year’s ASCO meeting is eagerly awaited for the unveiling of data on novel therapeutic classes including the Enhancer of Zeste Homolog 2 (EZH2) inhibitors, CYP11A1 inhibitors, DLL3-targeted immune therapies, and PROTAC degraders. The landscape of prostate cancer treatment has been significantly transformed by the PSMA path and lutetium-177. Other promising targets are being explored, such as human kallikrein 2 (hK2) with Janssen all set to reveal Phase I data from its actinium-225-labeled antibody, JNJ-69086420, which could open new avenues for treatment.

In the realm of bladder cancer, non-muscle invasive bladder cancer (NMIBC) is the most prevalent form, comprising about 75% of new cases. A major highlight at ASCO 2024 will be CG Oncology's final results from the CORE-001 Phase II trial of cretostimogene in combination with KEYTRUDA. The data is expected to indicate a potential positive shift in the treatment landscape for NMIBC, offering new hope for patients who do not respond to traditional BCG therapy.

Whereas, on the other hand, renal cell carcinoma is the most common type of kidney cancer accounting for around 90% of all kidney cancers. This year, the much-awaited final overall survival analysis from Pfizer's Phase III JAVELIN Renal 101 trial will be presented, providing critical insights into improving survival outcomes for RCC patients.

The top genitourinary cancer abstracts are listed below:

Genitourinary Cancer Key Abstracts